KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Common Equity (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Common Equity for 15 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly Common Equity rose 2.51% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 2.51% year-over-year, with the annual reading at $1.1 billion for FY2025, 2.51% up from the prior year.
  • Common Equity for Q4 2025 was $1.1 billion at Supernus Pharmaceuticals, up from $1.0 billion in the prior quarter.
  • The five-year high for Common Equity was $1.1 billion in Q2 2025, with the low at $754.4 million in Q1 2021.
  • Average Common Equity over 5 years is $918.8 million, with a median of $916.0 million recorded in 2023.
  • The sharpest move saw Common Equity increased 23.0% in 2021, then grew 1.87% in 2024.
  • Over 5 years, Common Equity stood at $815.9 million in 2021, then increased by 8.62% to $886.2 million in 2022, then increased by 3.98% to $921.5 million in 2023, then grew by 12.39% to $1.0 billion in 2024, then increased by 2.51% to $1.1 billion in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $1.1 billion, $1.0 billion, and $1.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.